China-based global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) announced on Wednesday that it has named Xu Wang as its new chief executive officer (CEO).
Wang succeeds Dave Chenn and Dr Hui Shao, who has stepped down from the company's interim CEO and co-CEO positions, respectively.
Wang has worked as the firm's chief operation officer since June 2024, and will no longer assume such role upon becoming the company's chief executive officer.
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial
Adcentrx's ADRX-0706 granted US FDA Fast Track designation to treat advanced cervical cancer
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
TransCode Therapeutics announces reverse stock split
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
TransCode Therapeutics reports progress in metastatic cancer trial
Ingenium Therapeutics' Gengleucel to enter Phase 2 trial in MRD+ AML following FDA feedback
AllyGPO and BioCareSD advance community oncology through integrated, tech-driven drug management
Nuformix receives positive EMA opinion for orphan drug designation of NXP002 in IPF
Atossa Therapeutics secures new US patent for proprietary (Z)-endoxifen formulations
Myosin Therapeutics receives grant to advance MT-110 clinical trial in methamphetamine use disorder